Association of serum CTRP4 levels with vascular endothelial function in patients with type 2 diabetes mellitus: CTRP4 ameliorating inflammation, proliferation and migration in human umbilical vein endothelial cells.

Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9200299 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-5233 (Electronic) Linking ISSN: 09405429 NLM ISO Abbreviation: Acta Diabetol Subsets: MEDLINE

Publication: Berlin : Springer Verlag
Original Publication: Berlin : Springer International, c1991-

Cell Movement* ; Cell Proliferation* ; Diabetes Mellitus, Type 2*/blood ; Human Umbilical Vein Endothelial Cells* ; Inflammation*; Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Adipokines/blood ; Endothelium, Vascular/metabolism ; NF-kappa B/metabolism

Objective: We investigated the correlation between serum C1q/TNF-related protein 4 (CTRP4) level and flow-mediated dilation (FMD) in patients with type 2 diabetes mellitus (T2DM), and evaluated the biological effects of CTRP4 on human umbilical vein endothelial cells (HUVECs).
Methods: A group of 165 patients diagnosed with T2DM were included in this study. Endothelial function was measured with the examination of brachial artery FMD. ELISA kit was used to measure the levels of CTRP4 in serum. HUVECs were stimulated with recombinant CTRP4 protein to assess its biological functions.
Results: The levels of CTRP4 showed a significant variation among three groups based on FMD tertiles (p = 0.001). What's more, FMD had a significant difference among three CTRP4 tertile groups (p < 0.05) and was negatively related to serum CTRP4 levels (r = -0.270, p < 0.001). In T2DM patients, logistic regression analysis demonstrated that CTRP4 was the primary influence factor of low FMD (p < 0.01). In receiver operating characteristic curve analysis, the area under the curve of CTRP4 for predicting low FMD was 0.66 (95%CI 0.58-0.75). When stimulated HUVECs with recombinant CTRP4 protein, we found that CTRP4 could concentration-dependently ameliorate proliferation and migration of HUVECs in wounding healing and transwell assay. This protein could also decrease the expression of IL-6 and TNF-α and promote the release of NO in HUVEC supernatants, with suppression of NF-κB and STAT3 phosphorylation.
Conclusions: Serum CTRP4 concentrations were negatively associated with FMD. CTRP4 alleviated proliferation, migration and inflammation in HUVECs through the suppression of NF-κB and STAT3 signaling pathways.
(© 2024. The Author(s).)

J Clin Invest. 2023 Nov 28;134(4):. (PMID: 38015631)
Biomed Res Int. 2015;2015:971683. (PMID: 26457306)
Nutrients. 2021 Aug 31;13(9):. (PMID: 34578930)
Atherosclerosis. 2011 May;216(1):7-16. (PMID: 21411098)
Trends Immunol. 2004 Oct;25(10):551-61. (PMID: 15364058)
J Am Coll Cardiol. 2001 Jul;38(1):111-6. (PMID: 11451259)
Eur J Immunol. 2021 Feb;51(2):380-392. (PMID: 33080044)
PLoS One. 2018 Jan 30;13(1):e0192159. (PMID: 29381773)
Int J Cardiol. 2013 Sep 20;168(1):344-51. (PMID: 23041097)
J Am Coll Cardiol. 1996 Mar 1;27(3):567-74. (PMID: 8606266)
J Diabetes Investig. 2022 Oct;13(10):1723-1731. (PMID: 35598316)
J Biol Chem. 2012 Jan 6;287(2):1576-87. (PMID: 22086915)
Atherosclerosis. 2004 May;174(1):49-56. (PMID: 15135250)
Pharmacol Rev. 2021 Jul;73(3):924-967. (PMID: 34088867)
Nat Rev Endocrinol. 2018 Feb;14(2):88-98. (PMID: 29219149)
Curr Med Chem. 2019;26(29):5579-5595. (PMID: 30009701)
Trends Endocrinol Metab. 2012 Apr;23(4):194-204. (PMID: 22261190)
Postgrad Med. 2014 Mar;126(2):38-53. (PMID: 24685967)
Biosci Rep. 2020 May 29;40(5):. (PMID: 32342981)
Diabetes Care. 2021 Jan;44(Suppl 1):S15-S33. (PMID: 33298413)
Lancet. 1992 Nov 7;340(8828):1111-5. (PMID: 1359209)
Cancer Lett. 2011 Sep 28;308(2):203-14. (PMID: 21658842)
Neuroscience. 2020 Mar 1;429:1-9. (PMID: 31917347)
Cytokine. 2019 Jan;113:326-331. (PMID: 30337217)
Cell Signal. 2017 Apr;32:36-47. (PMID: 28089769)
Future Cardiol. 2018 Nov;14(6):491-509. (PMID: 30409037)
Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10302-7. (PMID: 15231994)
Hypertension. 2011 Mar;57(3):363-9. (PMID: 21263128)
J Cardiol. 2010 Nov;56(3):307-13. (PMID: 20943346)
Cell Mol Immunol. 2017 Oct;14(10):868-870. (PMID: 29026217)
PLoS One. 2016 Dec 29;11(12):e0168773. (PMID: 28033351)
Clin Chim Acta. 2022 Jan 1;524:187-191. (PMID: 34801485)
FASEB J. 2008 May;22(5):1502-11. (PMID: 18171693)
Gen Pharmacol. 1996 Mar;27(2):221-38. (PMID: 8919635)
Atherosclerosis. 2019 Jul;286:1-6. (PMID: 31051410)
Clin Physiol Funct Imaging. 2009 May;29(3):170-6. (PMID: 19170724)
Int J Hypertens. 2022 Apr 30;2022:2432567. (PMID: 35535214)
Prostaglandins Other Lipid Mediat. 2018 Jan;134:131-140. (PMID: 28802571)
Int J Cardiol. 2017 Feb 1;228:129-136. (PMID: 27863353)
Eur Heart J. 2018 Sep 1;39(33):3021-3104. (PMID: 30165516)
Circulation. 2009 Feb 24;119(7):1005-12. (PMID: 19204308)
J Biol Chem. 2014 Feb 14;289(7):4055-69. (PMID: 24366864)
Nutrients. 2020 Jan 16;12(1):. (PMID: 31963378)
Diabetes Metab Res Rev. 2020 Jan;36(1):e3215. (PMID: 31508874)
Am J Physiol Endocrinol Metab. 2020 Dec 1;319(6):E1084-E1100. (PMID: 33017221)
FASEB J. 2009 Jan;23(1):241-58. (PMID: 18787108)
J Neuroinflammation. 2021 Jul 18;18(1):159. (PMID: 34275474)
Int J Mol Sci. 2022 Mar 20;23(6):. (PMID: 35328769)
Arterioscler Thromb Vasc Biol. 2015 Apr;35(4):1022-9. (PMID: 25657309)
Ther Adv Endocrinol Metab. 2021 Nov 30;12:20420188211059884. (PMID: 34868546)
Cell Mol Immunol. 2016 Sep;13(5):688-99. (PMID: 27086950)

2020tszk01 Clinical Characteristic of Health System in Putuo District, Shanghai; ZK2019B16 Shanghai Medical Key Specialties; ptkwws202003 Science, Technology Innovation Project of Putuo District Health System; ptkwws201911 Science, Technology Innovation Project of Putuo District Health System; 20204Y0154 Research Project of Shanghai Municipal Health Care Commission; 22-LY-03 Scientific Research of Shanghai Sixth Hospital Consortium

Keywords: CTRP4; Endothelial function; Flow-mediated dilation; Type 2 diabetes mellitus

0 (C1QTNF4 protein, human)

Date Created: 20240129 Date Completed: 20240427 Latest Revision: 20240522

20240522

PMC11055794

10.1007/s00592-023-02228-3

38286878